Guided Therapeutics (GTHP) 0.1700 $GTHP
Guided Therapeutics' (GTHP) CEO Gene Cartwright on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 1:54PM CDT
Guided Therapeutics Reports First Quarter 2015 Results
Business Wire - Wed May 13, 3:05PM CDT
--FDA response on amended LuViva PMA application expected by end of May
County Government of Nairobi, Kenya Purchases Initial LuViva(R) Advanced Cervical Scan for Cervical Cancer Screening Program
Business Wire - Wed May 06, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that Stem World Enterprises, its distributor for East Africa, has been awarded a contract with the Nairobi County Health Services Sector to supply the first LuViva(R) Advanced Cervical Scan for the agency's cervical cancer screening program.
Guided Therapeutics to Report First Quarter 2015 Results and Hold Conference Call; Provide Update on LuViva FDA Timing
Business Wire - Wed Apr 29, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a point-of-care and painless testing platform that uses biophotonics for the early detection of disease that leads to cervical cancer, today announced that it is scheduled to report financial results for its first quarter ended March 31, 2015 and provide an update on business activity on Wednesday, May 13, 2015, after the market closes.
Penny Stocks Alerts for NEW GENERATION CONSU, Vapor Group, Guided Therapeutics, Jammin Java, MassRoots, and Max Sound
PR Newswire - Tue Apr 21, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: NEW GENERATION CONSU (OTCMKTS:NGCG), Vapor Group (OTCMKTS:VPOR), Guided Therapeutics (OTCBB:GTHP), Jammin Java (OTCMKTS:JAMN), MassRoots (OTCMKTS:MSRT), and Max Sound (OTCBB:MAXD).
Canadian Pilot Programs Initiated with LuViva(R) Advanced Cervical Scan for Provincial-level Cancer Care Support
Business Wire - Tue Apr 21, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today an initiative for procuring provincial-level support for its LuViva Advanced Cervical Scan. The initiative is based on discussions with women's healthcare experts across Canada, whose interest has increased after reviewing positive results from two previous evaluations completed in Halifax, Nova Scotia, with Dr. James Bentley and most recently in London, Ontario, with Drs. Robert DiCecco and Monique Bertrand.
Week In Review: Menarini And Lummy Announce Novel Drug In-Licensings For China
ChinaBio Today - at Seeking Alpha - Sat Apr 18, 12:07PM CDT
Deals and Financings Menarini of Italy in-licensed China and Asia-Pacific rights to a proposed liver cancer treatment developed by Germany's 4SC AG for $100 million in upfront and milestone payments. Resminostat, 4SC's lead oncology compound, is an...
BSX: 18.06 (+0.21), ARGS: 7.88 (+0.20), PKI: 52.35 (+0.19)
Guided Therapeutics Completes Interim Financing; Initiating Distribution of LuViva(R) Advanced Cervical Scan in China
Business Wire - Wed Apr 15, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has completed the sale of 4.0 million shares of our common stock and warrants to purchase an additional 2.0 million shares, for an aggregate purchase price of $720,000 in a private placement to accredited investors.
Guided Therapeutics Ships First Commercial LuViva(R) Advanced Cervical Scans to Indonesia
Business Wire - Wed Apr 08, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has shipped two LuViva(R) Advanced Cervical Scans to Indonesia to begin cervical cancer screening evaluations in the world's fourth most populous country.
Guided Therapeutics Reports 2014 Results
Business Wire - Wed Mar 25, 3:05PM CDT
--2015 product sales forecast of over $3 million compared to 2014 product sales of $758,000
Guided Therapeutics Provides an Update on FDA Review Time for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Feb 03, 7:05AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the pre-market approval (PMA) application for the LuViva(R) Advanced Cervical Scan. The company has been in communication with the agency and is hoping to receive the agency's decision within the next several weeks.
Cervical Cancer Diagnostic Tests Market - 2014 Global Industry Analysis
M2 - Tue Dec 16, 5:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/q8j6pp/cervical_cancer) has announced the addition of the "Cervical Cancer Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends" report to their offering. The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations. Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp., Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Cervical Cancer Diagnostic Tests Market, by Type of Test Chapter 5 Global Cervical Cancer Diagnostics Tests Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles For more information visit http://www.researchandmarkets.com/research/q8...cal_cancer
DGX: 72.81 (+1.19), QGEN: 24.91 (+0.20), HOLX: 34.62 (+0.18)
Clinical Results Presented at Turkish Medical Congress Further Support LuViva(R) Advanced Cervical Scan for Primary Screening and Detection of Cervical Cancer
Business Wire - Thu Dec 04, 7:06AM CST
The LuViva(R) Advanced Cervical Scan continues to demonstrate the capability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods, according to recent studies presented at the 25th Turkish Society of Gynecology Oncology Congress.
Guided Therapeutics prices USD3.8m public offering of common stock and warrants
M2 - Thu Nov 27, 5:47AM CST
Biophotonic technology company Guided Therapeutics (OTC:BBGTHP) stated on Wednesday that it expects to raise gross proceeds (including non-cash extinguishment of debt) of approximately USD3.8m from public offering of common stock and warrant.
Guided Therapeutics prices offering
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 9:52AM CST
Guided Therapeutics Announces Pricing of $3.8 Million Public Offering
Business Wire - Wed Nov 26, 9:20AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 16.8 million shares of its common stock, and warrants to purchase shares of its common stock, for gross proceeds to the Company (including non-cash extinguishment of debt) of approximately $3.8 million. The shares and warrants are being offered at a combined price of $0.225 per share. Each warrant will be exercisable for five years to purchase one half of a share of the Company's common stock at an exercise price of $0.225 per share.
Nigerian Clinical Studies Demonstrate Advantages of LuViva(R) Advanced Cervical Scan for Screening and Detecting Cervical Pre-Cancer in Africa
Business Wire - Wed Nov 19, 7:05AM CST
Results of two clinical studies of the LuViva(R) Advanced Cervical Scan showed the versatility of the technology in its ability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods. The studies were presented at the Society of Gynecology and Obstetrics of Nigeria 2014 conference in Asaba, Nigeria, this week.
Guided Therapeutics Reports Third Quarter 2014 Results
Business Wire - Thu Nov 13, 3:49PM CST
--Product Sales up 30% Sequentially from Second Quarter
Guided Therapeutics' (GTHP) CEO Gene Cartwright on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 1:54PM CDT
Guided Therapeutics Reports First Quarter 2015 Results
Business Wire - Wed May 13, 3:05PM CDT
--FDA response on amended LuViva PMA application expected by end of May
County Government of Nairobi, Kenya Purchases Initial LuViva(R) Advanced Cervical Scan for Cervical Cancer Screening Program
Business Wire - Wed May 06, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that Stem World Enterprises, its distributor for East Africa, has been awarded a contract with the Nairobi County Health Services Sector to supply the first LuViva(R) Advanced Cervical Scan for the agency's cervical cancer screening program.
Guided Therapeutics to Report First Quarter 2015 Results and Hold Conference Call; Provide Update on LuViva FDA Timing
Business Wire - Wed Apr 29, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a point-of-care and painless testing platform that uses biophotonics for the early detection of disease that leads to cervical cancer, today announced that it is scheduled to report financial results for its first quarter ended March 31, 2015 and provide an update on business activity on Wednesday, May 13, 2015, after the market closes.
Penny Stocks Alerts for NEW GENERATION CONSU, Vapor Group, Guided Therapeutics, Jammin Java, MassRoots, and Max Sound
PR Newswire - Tue Apr 21, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: NEW GENERATION CONSU (OTCMKTS:NGCG), Vapor Group (OTCMKTS:VPOR), Guided Therapeutics (OTCBB:GTHP), Jammin Java (OTCMKTS:JAMN), MassRoots (OTCMKTS:MSRT), and Max Sound (OTCBB:MAXD).
Canadian Pilot Programs Initiated with LuViva(R) Advanced Cervical Scan for Provincial-level Cancer Care Support
Business Wire - Tue Apr 21, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today an initiative for procuring provincial-level support for its LuViva Advanced Cervical Scan. The initiative is based on discussions with women's healthcare experts across Canada, whose interest has increased after reviewing positive results from two previous evaluations completed in Halifax, Nova Scotia, with Dr. James Bentley and most recently in London, Ontario, with Drs. Robert DiCecco and Monique Bertrand.
Week In Review: Menarini And Lummy Announce Novel Drug In-Licensings For China
ChinaBio Today - at Seeking Alpha - Sat Apr 18, 12:07PM CDT
Deals and Financings Menarini of Italy in-licensed China and Asia-Pacific rights to a proposed liver cancer treatment developed by Germany's 4SC AG for $100 million in upfront and milestone payments. Resminostat, 4SC's lead oncology compound, is an...
BSX: 18.06 (+0.21), ARGS: 7.88 (+0.20), PKI: 52.35 (+0.19)
Guided Therapeutics Completes Interim Financing; Initiating Distribution of LuViva(R) Advanced Cervical Scan in China
Business Wire - Wed Apr 15, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has completed the sale of 4.0 million shares of our common stock and warrants to purchase an additional 2.0 million shares, for an aggregate purchase price of $720,000 in a private placement to accredited investors.
Guided Therapeutics Ships First Commercial LuViva(R) Advanced Cervical Scans to Indonesia
Business Wire - Wed Apr 08, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has shipped two LuViva(R) Advanced Cervical Scans to Indonesia to begin cervical cancer screening evaluations in the world's fourth most populous country.
Guided Therapeutics Reports 2014 Results
Business Wire - Wed Mar 25, 3:05PM CDT
--2015 product sales forecast of over $3 million compared to 2014 product sales of $758,000
Guided Therapeutics Provides an Update on FDA Review Time for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Feb 03, 7:05AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the pre-market approval (PMA) application for the LuViva(R) Advanced Cervical Scan. The company has been in communication with the agency and is hoping to receive the agency's decision within the next several weeks.
Cervical Cancer Diagnostic Tests Market - 2014 Global Industry Analysis
M2 - Tue Dec 16, 5:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/q8j6pp/cervical_cancer) has announced the addition of the "Cervical Cancer Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends" report to their offering. The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations. Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp., Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Cervical Cancer Diagnostic Tests Market, by Type of Test Chapter 5 Global Cervical Cancer Diagnostics Tests Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles For more information visit http://www.researchandmarkets.com/research/q8...cal_cancer
DGX: 72.81 (+1.19), QGEN: 24.91 (+0.20), HOLX: 34.62 (+0.18)
Clinical Results Presented at Turkish Medical Congress Further Support LuViva(R) Advanced Cervical Scan for Primary Screening and Detection of Cervical Cancer
Business Wire - Thu Dec 04, 7:06AM CST
The LuViva(R) Advanced Cervical Scan continues to demonstrate the capability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods, according to recent studies presented at the 25th Turkish Society of Gynecology Oncology Congress.
Guided Therapeutics prices USD3.8m public offering of common stock and warrants
M2 - Thu Nov 27, 5:47AM CST
Biophotonic technology company Guided Therapeutics (OTC:BBGTHP) stated on Wednesday that it expects to raise gross proceeds (including non-cash extinguishment of debt) of approximately USD3.8m from public offering of common stock and warrant.
Guided Therapeutics prices offering
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 9:52AM CST
Guided Therapeutics Announces Pricing of $3.8 Million Public Offering
Business Wire - Wed Nov 26, 9:20AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 16.8 million shares of its common stock, and warrants to purchase shares of its common stock, for gross proceeds to the Company (including non-cash extinguishment of debt) of approximately $3.8 million. The shares and warrants are being offered at a combined price of $0.225 per share. Each warrant will be exercisable for five years to purchase one half of a share of the Company's common stock at an exercise price of $0.225 per share.
Nigerian Clinical Studies Demonstrate Advantages of LuViva(R) Advanced Cervical Scan for Screening and Detecting Cervical Pre-Cancer in Africa
Business Wire - Wed Nov 19, 7:05AM CST
Results of two clinical studies of the LuViva(R) Advanced Cervical Scan showed the versatility of the technology in its ability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods. The studies were presented at the Society of Gynecology and Obstetrics of Nigeria 2014 conference in Asaba, Nigeria, this week.
Guided Therapeutics Reports Third Quarter 2014 Results
Business Wire - Thu Nov 13, 3:49PM CST
--Product Sales up 30% Sequentially from Second Quarter
